SHANDONG XINHUA_Providing professional financial news and data related to SHANDONG XINHUA, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Dapagliflozin Tablets

Tags：

SHANDONG XINHUA 00719.HK R&D Progress

2026-08-21

Research
HK Stock Connect Daily Report: MINIMAX-W Up Nearly 12%, Z.AI Up Over 10%, Southbound Net Sell of HKD 7.6 Billion - 20260821
Finance
Ingenic Semiconductor (03223.HK): H-Shares Offer Price Set at HK$100 Per Share
Finance
MOBVOI (02438.HK): Expects H1 Loss of RMB 45-58 Million
Finance
FAR INTL (02516.HK): Expects H1 Revenue Up 61%-110% and Turnaround or Narrower Loss
Finance
SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Dapagliflozin Tablets
Finance
LEADS BIOLABS-B (09887.HK): NDA for Virexin as Treatment for Extrapulmonary Neuroendocrine Carcinoma Accepted by NMPA
Finance
SC HOLDINGS (00413.HK): Expects H1 Net Loss of HKD 400-500 Million
Finance
HK shares ETFs Daily Report: Gold Miners Extend Gains 5.7%! Blockchain and Korea Counterattack in Tandem, Biomedicine and MedTech Lead Declines - 20260821
ETF
Ishares Ftse China A50 Etf (02823.HK) Rises 1.20% Intraday, Asset Size Reaches HK $14.888 Billion
ETF
CSOP SZSE ChiNext ETF (03147.HK) Rises 1.76% Intraday at HK$14.44

Scan QR Code

Download App